Development
Wave Life's RNA editing oligonucleotide restores wild-type M-AAT in early AATD trial
Wave Life Sciences (Nasdaq: WVE), based in Cambridge, Massachusetts, reported updated data from its Phase Ib/IIa WVE-006 RestorAATion-2 trial showing that...
BeOne appears to call time on EGFR degrader program
BeOne Medicines (formerly BeiGene; Basel, Switzerland; Nasdaq: ONC) has terminated its Phase I clinical trial of BG-60366, an orally administered chimeric...
China's SmartNuclide puts GPA33-directed pretargeted radioimmunotherapy into Phase I for CRC
A first-in-human trial of SNA028, a two-step pretargeted radioimmunotherapy targeting the GPA33 antigen, has been registered at Tianjin Medical University...
CSPC's tissue factor-targeting ADC enters Phase I for advanced solid tumors
CSPC Pharmaceutical Group (HKEX: 1093) has initiated a first-in-human Phase I clinical trial of SYS6051, a tissue factor (TF)-targeting antibody-drug...
Cellio Therapeutics' iPSC-derived retinal pigment epithelium C.001 enters Phase I for RPE-mediated maculopathy
Cellio Therapeutics has opened a first-in-human Phase I trial of C.001, an autologous iPSC-derived retinal pigment epithelium cell therapy, in adults with...
Mestag's FAP-targeted lymphotoxin agonist aims to engineer tertiary lymphoid structures in cold tumors
Mestag Therapeutics, a Cambridge, UK-based clinical-stage biotech, has dosed the first patient in the STARLYS trial, a Phase I study evaluating MST-0312, a...
Relay Therapeutics' zovegalisib achieves 60% response rate in Phase II PIK3CA vascular anomalies trial
Relay Therapeutics (Nasdaq: RLAY) has reported initial zovegalisib clinical data from the Phase II ReInspire trial in PIK3CA-driven vascular anomalies,...
iECURE's ECUR-506 achieves 57% reduction in hyperammonemic events in OTC deficiency trial
iECURE reported statistically significant reductions in hyperammonemic events from the ECUR-506 OTC-HOPE trial, with the completed low-dose cohort showing a...
AeroRx posts positive Phase II data for nebulized LABA/LAMA drug in COPD
AeroRx Therapeutics has reported Phase 2a data for AERO-007, a nebulized fixed-dose combination of indacaterol and glycopyrrolate, showing statistically...
Nanobiotix's JNJ-1900 produces strong early Phase II data in stage III lung cancer
Nanobiotix (Euronext: NANO; Nasdaq: NBTX) reported an 85.7% overall response rate and a 57.1% complete response rate in seven patients with stage III...
Ipsen hopeful for corabotase as Botox alternative after positive Phase II
Ipsen (Euronext: IPN; ADR: IPSEY) reported Phase II data for corabotase in moderate-to-severe glabellar lines showing that 60.8% of patients maintained a...
Novartis posts data for Pluvicto in indication-expanding prostate cancer trial
Novartis (SWX: NOVN) reported new data from the Phase III PSMAddition trial showing that lutetium (177Lu) vipivotide tetraxetan (Pluvicto) reduced the risk...
BioMarin faces uncertainty for ENPP1 enzyme replacement therapy after mixed Phase III
BioMarin Pharmaceutical (Nasdaq: BMRN) reported that its Phase III ENERGY 3 trial evaluating BMN 401 in children aged 1 to 12 with ENPP1 deficiency met only...
Biotheryx's CDK4/6 degrader produces 80% clinical benefit in Phase I breast cancer trial
Biotheryx reported Phase I dose escalation data for BTX-9341, a first-in-class oral CDK4/6 bifunctional degrader, showing a clinical benefit rate of 80% in...
Vincentage Pharma's oral GLP-1 achieves 12% weight loss in China Phase III
Vincentage Pharma, a Chengdu-based metabolic disease company, reported that VCT220, its oral small-molecule GLP-1 receptor agonist, produced mean body...
The AllSci Brief
Systematic R&D and deal news. Daily.